Laura Crawford is a pharmacologist, board-certified toxicologist, and regulatory affairs professional. She is a Senior Director of Drug Development at Orange Grove Bio, a biotech holding company focused on innovations in the inflammatory, autoimmune, and oncology disease areas. She also serves as COO of the portfolio companies, IpiNovyx Bio and Allonix.
For the past 10 years Crawford has worked in various positions of increasing responsibility which focus on drug discovery, development, and operations. Crawford has expertise in identifying novel drug candidates and moving them strategically into development programs. She has specialty in small molecules for oncology, dermal, and autoimmune indications. At Orange Grove Bio, Crawford works with portfolio companies and oversees programs from discovery and IND candidate selection through IND submission and early clinical development.

Prior to joining Orange Grove Bio, Crawford worked at Athenex, where she led the nonclinical development efforts for 5 clinical products, primarily in oncology. More recently, Crawford worked as an Associate Principal Consultant at SciLucent, providing advisement on nonclinical development strategy and study execution, and as the Senior Director of Drug Development at Nirogy Therapeutics.

Laura has contributed to numerous investigational new drug applications (INDs) and new drug applications (NDAs), and was a key contributor to the development of Klisyri® (tirbanibulin) from early preclinical development through FDA/EMA approval.
Laura holds a B.S. in Biology from Canisius College and a Ph.D. in Pharmacology and Therapeutics from SUNY Buffalo. She is a certified Diplomate of the American Board of Toxicology (DABT) and maintains Regulatory Affairs Certification (RAC).